Opportunity Information: Apply for RFA DA 11 009
Apply for RFA DA 11 009
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "2011 NIDA Translational Avant Garde Award for Medication Development for Diseases of Addiction (DP1)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Feb 3, 2011 and posted on Feb 3, 2011.
- Applicants must submit their applications by Jun 27, 2011. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $1,500,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $500,000.00 in funding.
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification) Small businesses State governments County governments Special district governments Private institutions of higher education Independent school districts City or township governments Public housing authorities/Indian housing authorities For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) Native American tribal organizations (other than Federally recognized tribal governments) Public and State controlled institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The 2011 NIDA Translational Avant Garde Award for Medication Development for Diseases of Addiction (DP1) is a National Institutes of Health funding opportunity from the National Institute on Drug Abuse (NIDA) aimed at pushing promising science across the gap between discovery and real-world addiction treatments. The program is built for basic and clinical researchers who have the vision and capability to translate findings into actual medications that are safe and effective for substance use disorders. NIDA frames the goal as making meaningful advances in treatment options for addiction related to tobacco, cannabis, cocaine, methamphetamine, heroin, and prescription opioids, with the expectation that the supported work will move beyond early ideas and into clear translational progress toward a viable therapeutic product.
The scope is explicitly focused on medication development and can include both traditional drugs and biologics. On the pharmaceutical side, this includes small-molecule compounds. On the biologics side, the announcement highlights products made through biological processes, such as vaccines and recombinant therapeutic proteins. Projects can target one addiction disorder or span multiple disorders, and proposals do not have to be limited to a single clinical endpoint. Applicants may instead focus on specific, treatment-relevant features of addiction such as withdrawal symptoms, craving, or relapse prevention, as long as the work remains tied to developing or advancing a medication-based intervention.
A notable element of the announcement is that it allows repurposing and optimization strategies, not just brand-new molecular entities. The FOA states that testing new formulations of already marketed medications (originally approved for other indications) is within scope, as is studying new combinations of existing medications if there is a sound rationale that they could be effective for addiction treatment. That inclusion makes the opportunity relevant to teams pursuing faster translational pathways, where safety profiles or manufacturing know-how may already exist and the key challenge is demonstrating efficacy, optimizing dosing or formulation, or proving value for a new addiction-related indication.
The competition structure for 2011 is described as a two-phase process. Phase one is a pre-application stage tied to a separate pre-application announcement (PAR-11-102). Those pre-applications are reviewed by external experts, and only the submissions judged most outstanding are invited forward. Investigators selected in that first round are notified by April 26 that they may submit a full application under this DP1 FOA (RFA-DA-11-009). Final Avant Garde awardees are chosen from the invited group, meaning the full application stage is effectively a second-round competition among the strongest pre-application candidates.
From an administrative standpoint, the opportunity is a discretionary grant using the DP1 activity code and is associated with CFDA 93.279 (Drug Abuse and Addiction Research Programs). The posting and creation dates are February 3, 2011. The closing date for full applications is June 27, 2011, and the archive date is July 28, 2011. NIDA lists an estimated total funding level of $1,500,000 and an award ceiling of $500,000, and it explicitly states that there is no cost sharing or matching requirement.
Eligibility is broad and includes many types of organizations across the public, private, and nonprofit sectors. Eligible applicants include small businesses; for-profit organizations (including those other than small businesses); nonprofits (both 501(c)(3) and non-501(c)(3) entities, other than institutions of higher education); private and public institutions of higher education; state, county, city/township, special district, and independent school district governments; public housing authorities/Indian housing authorities; and federally recognized tribal governments as well as tribal organizations. The eligibility section also calls out additional categories such as Historically Black Colleges and Universities, Hispanic-serving institutions, Alaska Native and Native Hawaiian serving institutions, tribally controlled colleges and universities, faith-based or community-based organizations, regional organizations, U.S. territories or possessions, and non-U.S. entities (foreign organizations). Federal agencies are also listed as eligible. The practical takeaway is that NIDA intended this award to be accessible to a wide range of institutions capable of conducting translational medication development work, including academic labs, biotech-oriented teams, and multi-organization collaborations.
Overall, this FOA is essentially a targeted, high-impact mechanism meant to identify unusually strong investigators and give them support to move addiction treatment candidates forward, whether that means advancing a novel compound, developing a vaccine approach, creating a recombinant therapeutic protein, or repurposing and reformulating existing medications in a way that could materially improve outcomes for withdrawal, craving, or relapse. The official announcement is identified as RFA-DA-11-009 and is hosted through the NIH Grants Guide.
Frequently Asked Questions (FAQs)
What is the 2011 NIDA Translational Avant Garde Award for Medication Development for Diseases of Addiction (DP1)?
It is a National Institutes of Health (NIH) funding opportunity administered by the National Institute on Drug Abuse (NIDA) to push promising science across the gap between discovery and real-world addiction treatments. The award is designed for investigators who can translate research findings into medication-based treatments that are safe and effective for substance use disorders.
What is the official funding opportunity announcement (FOA) number?
The FOA is identified as RFA-DA-11-009 (hosted through the NIH Grants Guide).
What is the main goal of this funding opportunity?
The goal is to make meaningful advances in treatment options for addiction by supporting translational progress toward a viable therapeutic product. NIDA emphasizes moving beyond early ideas and demonstrating clear advancement toward real-world, medication-based interventions.
Which addiction areas are specifically mentioned as targets?
NIDA describes addiction-related treatment needs connected to tobacco, cannabis, cocaine, methamphetamine, heroin, and prescription opioids.
Is this opportunity focused on medications only, or can it fund other types of interventions?
The scope is explicitly focused on medication development. The description centers on advancing medication-based interventions, including traditional drugs and biologics.
What types of products are considered within scope (drugs vs. biologics)?
The opportunity includes both:
- Traditional pharmaceutical approaches, including small-molecule compounds.
- Biologics made through biological processes, including vaccines and recombinant therapeutic proteins.
Can a project focus on one substance use disorder, or must it address multiple disorders?
Projects can target one addiction disorder or span multiple disorders.
Do proposals have to be limited to a single clinical endpoint?
No. The information provided indicates proposals do not have to be limited to a single clinical endpoint.
Can an application focus on specific features of addiction (like craving or withdrawal) rather than a broad disorder outcome?
Yes. Applicants may focus on treatment-relevant features such as withdrawal symptoms, craving, or relapse prevention, as long as the work remains tied to developing or advancing a medication-based intervention.
Are repurposing or optimization approaches allowed, or does the program require entirely new drugs?
Repurposing and optimization strategies are explicitly allowed. The scope includes work that is not limited to brand-new molecular entities.
Can the award support testing a new formulation of an already marketed medication that was approved for a different indication?
Yes. The FOA states that testing new formulations of already marketed medications (originally approved for other indications) is within scope.
Can the award support new combinations of existing medications?
Yes. Studying new combinations of existing medications is within scope when there is a sound rationale that the combination could be effective for addiction treatment.
Who is this award designed for (basic vs. clinical researchers)?
The program is built for basic and clinical researchers who have the vision and capability to translate findings into actual medications for substance use disorders.
How does the 2011 competition process work?
The 2011 competition is described as a two-phase process:
- A pre-application stage under a separate pre-application announcement (PAR-11-102).
- A full application stage under the DP1 FOA (RFA-DA-11-009), open only to applicants invited after pre-application review.
Is a pre-application required before submitting a full application?
Yes. Phase one is a pre-application stage tied to PAR-11-102, and only those judged most outstanding are invited to submit a full application under RFA-DA-11-009.
Who reviews the pre-applications?
Pre-applications are reviewed by external experts, and only the submissions judged most outstanding are invited forward.
When are investigators notified about being invited to submit a full application?
Investigators selected in the first round are notified by April 26 that they may submit a full application under RFA-DA-11-009.
What is the application deadline for full applications?
The closing date for full applications is June 27, 2011.
When was this opportunity posted?
The posting and creation dates are February 3, 2011.
What is the archive date for this FOA?
The archive date is July 28, 2011.
What is the estimated total funding level and the maximum award amount?
NIDA lists an estimated total funding level of $1,500,000 and an award ceiling of $500,000.
Is cost sharing or matching required?
No. The FOA explicitly states there is no cost sharing or matching requirement.
What is the funding mechanism and activity code?
This is described as a discretionary grant using the DP1 activity code.
What CFDA number is associated with this opportunity?
The opportunity is associated with CFDA 93.279 (Drug Abuse and Addiction Research Programs).
What types of organizations are eligible to apply?
Eligibility is broad and includes many public, private, and nonprofit organization types, including:
- Small businesses
- For-profit organizations (including those other than small businesses)
- Nonprofits (501(c)(3) and non-501(c)(3), other than institutions of higher education)
- Private and public institutions of higher education
- State, county, city/township, special district, and independent school district governments
- Public housing authorities/Indian housing authorities
- Federally recognized tribal governments and tribal organizations
- U.S. territories or possessions
- Non-U.S. entities (foreign organizations)
- Federal agencies
Are minority-serving institutions and tribally controlled colleges/universities included in eligibility?
Yes. The eligibility section calls out categories including Historically Black Colleges and Universities, Hispanic-serving institutions, Alaska Native and Native Hawaiian serving institutions, and tribally controlled colleges and universities.
Are faith-based or community-based organizations eligible?
Yes. Faith-based or community-based organizations are explicitly listed among eligible applicant categories.
Are collaborations across different organization types consistent with the intent of the FOA?
The description emphasizes broad eligibility and notes applicability to academic labs, biotech-oriented teams, and multi-organization collaborations capable of conducting translational medication development work.
How are final awardees selected?
Final Avant Garde awardees are chosen from the invited group, meaning the full application stage functions as a second-round competition among the strongest pre-application candidates.
What kinds of translational progress does NIDA appear to be looking for?
Based on the description, NIDA expects supported work to move beyond early ideas and show clear translational progress toward a viable therapeutic product, whether that involves advancing a novel compound, developing a vaccine approach, creating a recombinant therapeutic protein, or repurposing/reformulating existing medications for addiction-related indications.
Browse more opportunities from the same category: Education Health
Next opportunity: SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization (R44)
Previous opportunity: Pre Application for the 2011 NIDA Translational Avant Garde Award for Medication Development for Diseases of Addiction (X02)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DA 11 009
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DA 11 009) also looked into and applied for these:
| Funding Opportunity |
|---|
| SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization (R44) Apply for RFA CA 11 002 Funding Number: RFA CA 11 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,000,000 |
| Predictive Animal Models for Smoking Cessation Medications (U54) Apply for RFA DA 11 014 Funding Number: RFA DA 11 014 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Centers for AIDS Research and Developmental Centers for AIDS Research (P30) Apply for PAR 11 108 Funding Number: PAR 11 108 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Grand Opportunity in Medications Development for Substance Related Disorders (U01) Apply for PAR 11 109 Funding Number: PAR 11 109 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellows (Parent F31) Apply for PA 11 111 Funding Number: PA 11 111 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NINR Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellows In Nursing Research (F31) Apply for PAR 11 117 Funding Number: PAR 11 117 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Limited Competition Specific pathogen free macaque colonies (U42) Apply for PAR 11 116 Funding Number: PAR 11 116 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Limited Competition Specific pathogen free macaque colonies (U24) Apply for PAR 11 115 Funding Number: PAR 11 115 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| HIV/AIDS Implementation Science Targeting Drug Using Populations A Collaboration with PEPFAR (R01) Apply for RFA DA 12 002 Funding Number: RFA DA 12 002 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| The Placebo Effect Mechanisms and Methodology (R21) Apply for RFA DA 12 004 Funding Number: RFA DA 12 004 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| The Placebo Effect Mechanisms and Methodology (R01) Apply for RFA DA 12 003 Funding Number: RFA DA 12 003 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Childhood Cancer Survivor Study (CCSS)(Limited Competition U24) Apply for RFA CA 11 501 Funding Number: RFA CA 11 501 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Medication Initiative for Tobacco Dependence (MITD) A New Product Development Partnership (PDP)(UH2/UH3) Apply for RFA DA 11 015 Funding Number: RFA DA 11 015 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Research Centers in Minority Institutions Program (G12) Apply for PAR 11 132 Funding Number: PAR 11 132 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NLM Institutional Training Grants for Research Training in Biomedical Informatics (T 15) Apply for RFA LM 11 001 Funding Number: RFA LM 11 001 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Limited Competition National Primate Research Centers (P51) Apply for PAR 11 136 Funding Number: PAR 11 136 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Development and Translation of Medical Technologies to Reduce Health Disparities (R43/R44) Apply for RFA EB 11 001 Funding Number: RFA EB 11 001 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Quantitative Imaging for Evaluation of Responses to Cancer Therapies (U01) Apply for PAR 11 150 Funding Number: PAR 11 150 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Strategic Partnering to Evaluate Cancer Signatures SPECS II (U01) Apply for PAR 11 151 Funding Number: PAR 11 151 Agency: National Institutes of Health Category: Education Health Funding Amount: $680,000 |
| The Role of Microbial Metabolites in Cancer Prevention and Etiology (U01) Apply for PAR 11 152 Funding Number: PAR 11 152 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DA 11 009", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.